The 'grey market' peptide phenomenon has been making headlines in recent years, with some enthusiasts claiming these injectable amino acids are a game-changer for everything from anti-ageing to muscle recovery. But behind the hype lies a worrying lack of evidence about their safety and effectiveness in humans – a concern echoed by medical experts who warn that the unregulated market poses significant risks.
Regulatory bodies, including advisers to the US Food and Drug Administration (FDA), are taking steps to address these concerns. In July, the FDA's pharmacy compounding advisory committee will convene to discuss seven peptides: BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, and Epitalon. These substances have been sold through unregulated 'grey market' channels, often by compounding pharmacies – some of which are reportedly based in China – and promoted online by social media influencers.
Some proponents argue that easing restrictions would bring these peptides into a more formal status, but it's essential to understand the distinction between 'approved' and 'eased restriction'. Traditional drug approval requires extensive clinical trials to establish specific health claims, risks, and side effects. The peptides in question have limited data, with some studies only conducted on animals.
The debate around these substances has been ongoing since 2023, when the Biden administration banned compounding pharmacies from producing 19 research peptides due to safety concerns, including potential risks of priapism and tumour growth. A recent survey suggests that most physicians are uneasy about the safety of these peptides, in contrast to some pharmacy industry representatives.
This US regulatory discussion has implications for international health policy, as countries like the UK grapple with their own guidelines for drug approval and prescription. The NHS prioritises treatments backed by robust evidence, ensuring patients receive safe and effective care – a standard that any newly 'eased restriction' peptides would need to meet.